 In a variety of clinical studies upon which FDA approval is based, Neumega showed effectivity in reducing thrombocytopenia in oncologic patients treated with myelosuppressant chemotherapeutic drugs as measured by significantly decreased need of platelet transfusions.Neumega is manufactured and sold by Wyeth.The drug is formulated in single-use vials containing 5 mg of oprelvekin (specific activity approximately 8 × 106 Units/mg) as a sterile, lyophilized powder.